Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RDHL 
Redhill Biopharma Ltd (RDHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: RDHL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $19000
1 Year Target Price $19000
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68.86% | Avg. Invested days 17 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.46M USD | Price to earnings Ratio - | 1Y Target Price 19000 |
Price to earnings Ratio - | 1Y Target Price 19000 | ||
Volume (30-day avg) 1 | Beta 4.56 | 52 Weeks Range 1.06 - 8.75 | Updated Date 10/26/2025 |
52 Weeks Range 1.06 - 8.75 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -97.52% | Operating Margin (TTM) -107.33% |
Management Effectiveness
Return on Assets (TTM) -25.32% | Return on Equity (TTM) -1708.61% |
Valuation
Trailing PE - | Forward PE 1428.57 | Enterprise Value 4740282 | Price to Sales(TTM) 0.57 |
Enterprise Value 4740282 | Price to Sales(TTM) 0.57 | ||
Enterprise Value to Revenue 0.5 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 3329860 | Shares Floating 16654500537 |
Shares Outstanding 3329860 | Shares Floating 16654500537 | ||
Percent Insiders - | Percent Institutions 2.63 |
Upturn AI SWOT
Redhill Biopharma Ltd
Company Overview
History and Background
Redhill Biopharma Ltd. is a specialty biopharmaceutical company, established in 2009, primarily focused on gastrointestinal diseases and infectious diseases. It aims to develop and commercialize innovative drugs to address unmet medical needs.
Core Business Areas
- Gastrointestinal Diseases: Develops and commercializes therapies for gastrointestinal disorders, including Crohn's disease, ulcerative colitis, and other GI ailments.
- Infectious Diseases: Focuses on developing therapies to combat infectious diseases, with current projects in COVID-19 and other viral infections.
Leadership and Structure
The company's leadership team consists of experienced pharmaceutical executives and scientists. It operates with a typical biopharmaceutical organizational structure, including research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- Movantik: Movantik (naloxegol) is an oral peripherally acting mu-opioid receptor antagonist (PAMORA) approved for opioid-induced constipation (OIC) in adults with chronic non-cancer pain. RedHill acquired US rights to Movantik. Competitors include other PAMORAs like Relistor (methylnaltrexone bromide) and Amitiza (lubiprostone).
- Talicia: Talicia is an oral fixed-dose combination of omeprazole, amoxicillin and rifabutin, approved for the treatment of Helicobacter pylori (H. pylori) infection. While specific market share data is variable, competitors include clarithromycin-based triple therapies, bismuth-based quadruple therapies, and other proton pump inhibitor (PPI) combinations.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and strong competition. There is a constant demand for innovative treatments, especially in areas like gastroenterology and infectious diseases.
Positioning
Redhill Biopharma Ltd positions itself as a specialty pharma company focusing on niche markets and unmet medical needs. It aims to differentiate itself through targeted therapies and strategic partnerships.
Total Addressable Market (TAM)
The TAM for gastrointestinal and infectious disease therapeutics is substantial, potentially worth billions of dollars annually. Redhill Biopharma Ltd's current product portfolio addresses segments of this TAM.
Upturn SWOT Analysis
Strengths
- Specialized focus on gastrointestinal and infectious diseases
- Approved products with established revenue streams
- Strategic partnerships for product development and commercialization
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a few key products for revenue
- Exposure to regulatory risks and clinical trial failures
- High marketing costs to generate revenue
Opportunities
- Expansion into new therapeutic areas within gastroenterology and infectious diseases
- Acquisition or licensing of promising drug candidates
- Geographic expansion into new markets
- Development of novel drug delivery systems
Threats
- Competition from larger pharmaceutical companies with greater resources
- Patent expirations and generic competition
- Changes in regulatory requirements
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- AGN
- MRK
- ABBV
Competitive Landscape
Redhill Biopharma Ltd. faces intense competition from larger pharmaceutical companies with greater resources. It needs to innovate and capitalize on niche markets to succeed. The company's nimbleness and focus on specific therapeutic areas provide a competitive advantage. However, the other larger companies have far more resources to perform R&D and marketing.
Major Acquisitions
Movantik (US Rights)
- Year: 2020
- Acquisition Price (USD millions): 52.5
- Strategic Rationale: To expand Redhill's gastrointestinal product portfolio with an approved and commercialized product.
Growth Trajectory and Initiatives
Historical Growth: Redhill Biopharma Ltd's historical growth has been driven by the acquisition and commercialization of new products, and organic sales. There are periods of decline and spikes as their growth is tied to FDA approvals and new product revenues.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercial launch of new products. Analyst estimates vary depending on market conditions and company performance.
Recent Initiatives: Recent initiatives include ongoing clinical trials for new therapies, strategic partnerships to expand their product portfolio, and efforts to commercialize their existing products.
Summary
Redhill Biopharma Ltd is a specialty biopharmaceutical company with approved products targeting gastrointestinal and infectious diseases. It faces competition from larger pharmaceutical companies. Key growth drivers include successful clinical trials and strategic acquisitions. The company needs to manage its financial resources effectively to support its growth initiatives.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-Party Market Research Reports
- Public News Articles
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. The information is subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Redhill Biopharma Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2013-01-07 | Co-Founder, Chairman & CEO Mr. Dror Ben-Asher | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 35 | Website https://www.redhillbio.com |
Full time employees 35 | Website https://www.redhillbio.com | ||
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.